Medical Management News
-
CUREO on the palliative care ward of the Charité hospital
We had already reported that CUREosity will be working with the Charité in the future - a cooperation that we are very pleased about. After all, with around 100 clinics and institutes on four campuses, Charité is one of the largest university hospitals in Europe. Together with Prof. Dr. Christoph Ploner, Prof. Dr. Carsten Finke and the physicians of the Department of Neurology with ...
-
Join us at AACC 2022
As a leading company for AI-Driven IVD equipments, Reetoo will be attending AACC (American Association for Clinical Chemistry), which will take place at the McCormick Place Convention Center in Chicago from July 26 to 28. We will bring our latest products to the exhibition as below, and look forward to meeting you at our booth #4060. RT-F600: Automatic Vaginal Secretion Analyzer ...
-
Making an impact in day-to-day care for patients at Saintonge Hospital
Barely two months after becoming the first hospital in France to install Dexter®, the team at Saintonge Hospital has scaled its on-demand robotics program into daily use. On pace to carry out 2-3 procedures per day with Dexter between the urology, gynecology and general surgery team, Saintonge Hospital’s pioneering effort is making meaningful progress towards establishing a new standard ...
-
Pixium Vision expands its Board of Directors with the appointment of Anja Krammer and August Moretti
Paris, France, June 24, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the appointment of Anja Krammer and August Moretti as members of the company's Board of Directors. Ms. ...
-
First Dexter surgeries in urology carried out in Bern
Today we are announcing the successful completion of urological surgeries with Dexter® – the first and only on-demand robotic surgery platform. In a world-first, Dr. Dominik Böhlen carried out a series of urological procedures using our novel, Swiss-made surgical robot. Dr. Böhlen and his team leveraged Dexter to assist them in the most difficult work steps during various ...
-
EsoCap Announces Publication “Development of a HotMelt Extrusion-Based Spinning Process to Produce Pharmaceutical Fibers and Yarns”
EsoCap has announced that scientists from the University of Greifswald have published important data regarding a hot-melt extrusion-based spinning process to produce pharmaceutical fibers and yarns. This spinning process is very useful in the context of EsoCap’s novel drug delivery technology, enabling targeted and long-lasting local therapy of the esophagus. The rapidly dissolving yarn is ...
By EsoCap AG
-
iRhythm launches Clinical Resource Center for clinicians’ convenience
iRhythm Technologies, Inc. is excited to announce the addition of a Clinical Resource Center (CRC) to its website. The CRC was designed to make it easy for clinicians to access clinical evidence, on-demand webinars, and case studies through one centralized location. Clinicians will use the CRC as a gateway to published clinical articles. Summaries of significant ...
-
Vividion Therapeutics names Aleksandra Rizo as President and Head of Research and Development
Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Aleksandra Rizo, M.D., Ph.D., will join the company as President and Head of ...
By Bayer AG
-
electroCore Announces Listing Transfer to the Nasdaq Capital Market
electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has received approval from the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. The Company's common stock will continue to be traded under the symbol "ECOR" ...
-
Neutron Therapeutics and University Hospital of Brussels Announce Their Collaboration to Offer Cancer Patients a Revolutionary New Treatment Method at Institut Jules Bordet
BOSTON & BRUSSELS--(BUSINESS WIRE)--Neutron Therapeutics, Inc (NT) and the University Hospital of Brussels (H.U.B) today announced that they have signed a Letter of Intent to place a nuBeam® suite for Boron-Neutron Capture Therapy (BNCT) at the Institut Jules Bordet (IJB), Erasmus Campus, Anderlecht. nuBeam® is the world’s safest and most powerful accelerator-based neutron ...
-
Neutron Therapeutics and University Hospital of Brussels Announce Their Collaboration to Offer Cancer Patients a Revolutionary New Treatment Method at Institut Jules Bordet
BOSTON & BRUSSELS--(BUSINESS WIRE)--Neutron Therapeutics, Inc (NT) and the University Hospital of Brussels (H.U.B) today announced that they have signed a Letter of Intent to place a nuBeam® suite for Boron-Neutron Capture Therapy (BNCT) at the Institut Jules Bordet (IJB), Erasmus Campus, Anderlecht. nuBeam® is the world’s safest and most powerful accelerator-based neutron ...
-
Check-Cap Ltd. (NASDAQ: CHEK) Announces Receipt of Extension to Meet the Nasdaq`s Minimum Bid Price Requirement
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), announces that onJune 22, 2022, it received a letter from The Nasdaq Stock Market LLC ...
-
Hummingbird Diagnostics Publishes Study of miRisk as a Predictor of Immunotherapy Efficacy in Advanced-Stage NSCLC
Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research Reports Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic ...
-
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval Positive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise interval TSC was safe and well-tolerated by all subjects with no serious adverse events reported Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) ...
By CervoMed
-
Coming Soon – The next addition to the EMPOWR Platform
EMPOWR Acetabular™ is DJO’s modern, premium, intelligently designed acetabular system featuring advanced fixation technologies, efficient instrumentation, and a feature enabling future dual mobility offering.1 This system – combined with our femoral stem options which all have 12/14 robust micro-threaded trunnions – provides surgeons a comprehensive THA solution for all ...
-
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
Ziphius Vaccines is developing a proprietary self-amplifying mRNA technology platform combined with innovative lipid formulations for delivery. saRNA or replicon RNA has the advantage of having self-replicating features, as the saRNA molecule encodes a viral RNA replicase in addition to the sequence of the protein(s) of interest. This mechanism leads to enhanced and prolonged protein ...
-
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced completion of the formulation study for its third asset, CTx-2103, for the management of anxiety-related disorders. The study was ...
By Cingulate
-
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy. The amendment increases the study duration for patients to 48 ...
-
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated approval application Q4 2022: Expected initiation of randomized, controlled evaluation in primary GBM patients as part ...
-
Aikening Launch in Azerbaijan
Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual therapy to treat people living with HIV who have failed initial treatment. The approval of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you